Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Liver Regeneration01:24

Liver Regeneration

4.1K
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
4.1K
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

1.3K
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
1.3K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

382
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

28
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
28
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

42
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
42

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Medial minimally invasive helical plate osteosynthesis of the distal femur - a new technique.

Injury·2020
Same author

Measurement of the centrality dependence of the charged-particle pseudorapidity distribution in proton-lead collisions at [Formula: see text] TeV with the ATLAS detector.

The European physical journal. C, Particles and fields·2017
Same author

Jet energy measurement and its systematic uncertainty in proton-proton collisions at [Formula: see text] TeV with the ATLAS detector.

The European physical journal. C, Particles and fields·2015
Same author

Kinetics and dynamics of cyclosporine A in three hepatic cell culture systems.

Toxicology in vitro : an international journal published in association with BIBRA·2015
Same author

Measurement of the inclusive jet cross-section in <i>pp</i> collisions at [Formula: see text] and comparison to the inclusive jet cross-section at [Formula: see text] using the ATLAS detector.

The European physical journal. C, Particles and fields·2015
Same author

Measurement of the charge asymmetry in top quark pair production in <i>pp</i> collisions at [Formula: see text] using the ATLAS detector.

The European physical journal. C, Particles and fields·2015

Related Experiment Video

Updated: May 2, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

56.5K

New challenges in hepatic fibrosis

B Clément1, O Loréal, F Levavasseur

  • 1Institut National de la Santé et de la Recherche Médicale, Unité de Recherches Hépatologiques, INSERM U-49, Hôpital Pontchaillou, Rennes, France.

Journal of Hepatology
|April 1, 1993
PubMed
Summary

Simple therapies for hepatic fibrosis, a condition leading to cirrhosis, are a future challenge. Research advances in extracellular matrix, cell origins, and cytokine roles offer new treatment avenues.

More Related Videos

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration
10:42

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration

Published on: May 13, 2016

8.6K
3D Imaging of the Liver Extracellular Matrix in a Mouse Model of Non-Alcoholic Steatohepatitis
06:46

3D Imaging of the Liver Extracellular Matrix in a Mouse Model of Non-Alcoholic Steatohepatitis

Published on: February 25, 2022

2.1K

Related Experiment Videos

Last Updated: May 2, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

56.5K
Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration
10:42

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration

Published on: May 13, 2016

8.6K
3D Imaging of the Liver Extracellular Matrix in a Mouse Model of Non-Alcoholic Steatohepatitis
06:46

3D Imaging of the Liver Extracellular Matrix in a Mouse Model of Non-Alcoholic Steatohepatitis

Published on: February 25, 2022

2.1K

Area of Science:

  • Hepatology and molecular biology.
  • Focuses on liver fibrosis mechanisms and potential therapies.

Background:

  • Hepatic fibrosis, a precursor to cirrhosis, affects millions globally and is linked to chronic liver diseases.
  • Recent decades have seen significant progress in understanding extracellular matrix components, protein synthesis/degradation, and cytokine roles in fibrogenesis.

Discussion:

  • In vitro models have been crucial for investigating the molecular underpinnings of fibrogenesis.
  • Research is actively pursuing reliable serum markers for fibrogenesis and developing drugs to prevent cirrhosis progression.

Key Insights:

  • Understanding the molecular mechanisms of extracellular matrix synthesis and degradation is key to treating hepatic fibrosis.
  • Cytokines, such as interferons, are being explored for their potential to modulate extracellular matrix synthesis as a therapeutic strategy.

Outlook:

  • Development of simple, inexpensive therapies for hepatic fibrosis is a critical future goal.
  • Continued research into fibrogenesis markers and anti-cirrhosis drugs holds promise for clinical applications.